The global meningococcal vaccines market size was valued at USD 2.88 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030. The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Moreover, increasing immunization programs, growing awareness about the disease, and increasing R&D activities pertaining to meningococcal vaccines are expected to fuel the market growth during the forecast period.
The overall market experienced a decline in 2020 owing to the COVID-19 pandemic. The net sales of Menactra, Menveo, Nimenrix, Trumenba, and Bexsero were negatively impacted in 2020. However, the market is expected to grow at a positive Y-o-Y growth rate in 2021 due to increasing initiatives by government and regulatory authorities to combat the rising prevalence of meningitis. For instance, in May 2019, the Ministry of Health of Ireland approved MenACWY vaccine to be provided to thousands of teenagers in Ireland, due to the rising prevalence of meningitis in 2018.
Various campaigns and awareness programs are being organized by government & non-government organizations, such as the National Meningitis Association (NMA), Meningitis Research Foundation of Canada, Meningitis B Action Project, and others. These organizations help in promoting continuous research and new approaches involved in disease prevention. Hence, these factors are anticipated to fuel the meningococcal vaccine market growth in the coming years.
The presence of non-profit organizations providing support for research projects, training to healthcare professionals, and offering information & help to patients is anticipated to accelerate market growth. For instance, in August 2021, DoSomething.Org and National Foundation for Infectious Diseases (NFID) introduced the "Complete What's Missing Program". The program's goal is to educate young people about the importance of Meningococcal Disease Prevention.
The presence of phase III vaccines in the pipeline which are expected to be commercialized over the forecast period is anticipated to fuel the market growth. For instance, in June 2020, Pfizer, Inc. initiated phase III clinical trials of PF-06886992, a pentavalent meningococcal vaccine candidate (MenABCWY) to assess & compare the safety, immunogenicity, and tolerability with licensed meningococcal vaccines in adolescents and young adults. Moreover, Menactra, a conjugate vaccine manufactured by Serum Institute of India Pvt. Ltd. is currently in phase III clinical trial.
Based on type, the market is segmented into bivalent, quadrivalent, and others. Quadrivalent vaccines accounted for the largest revenue share in 2021 owing to widely used brands such as Menactra, Menveo, and Nimenrix. Moreover, approval of new vaccines to protect people against meningococcal vaccines is anticipated to fuel the growth of this market. For instance, in April 2020, Sanofi received U.S. FDA approval for MenQuadfi. It is a quadrivalent meningococcal (Groups A, C, Y, W) conjugate vaccine for the prevention of invasive meningococcal disease in people 2 years & older.
Bivalent vaccines held the second largest market share owing to the high adoption rate coupled with the low cost and inclusion of these vaccines in various programs undertaken by governments of different countries. For instance, in China, MenA and MenAC are conjugate vaccines included in the multistage meningococcal vaccination program for children aged 6 to 18 months for MenA vaccine and aged 3 to 6 for MenAC vaccine. Apart from this, others segment consists of monovalent, trivalent, and pentavalent vaccines.
Based on brand segment, Bexsero accounted for the largest revenue share in 2021 owing to fewer doctor visits, lower costs and reduced doses. Bexsero is licensed in more than 40 countries, such as New Zealand, Argentina, Chile, Australia, Israel, Uruguay, Turkey, and Europe, and is intended for individuals aged 2 months & above. Moreover, the high adoption rate of the vaccine to protect against meningococcal infection caused by serotype B has increased the segment share.
Trumenba is expected to grow at the fastest rate over the forecast period. The growth of the vaccine is mainly driven by the increasing awareness of the disease and increasing marketing approval across the globe. For instance, in May 2017, the European Commission approved Pfizer, Inc.’s Trumenba to protect individuals aged 10 & above from IMD caused by MenB. Moreover, In July 2017, the U.K. approved Trumenba for individuals aged 10 and above. Thus, the segment is anticipated to grow at the highest rate.
Serotype B segment dominated the global market in 2021. This can be attributed to the presence of strong vaccines such as Trumenba & Bexsero available in the market and the increasing disease burden of MenB worldwide. In North America and the European region, Serotype B is the predominant agent causing meningococcal disease. It causes around half of the total reported cases of meningococcal disease in these regions. Moreover, increasing research activities to develop pentavalent vaccines including protection against serotype B is further expected to increase the market growth over the forecast period.
However, the serotype C segment is anticipated to experience the fastest growth over the forecast period. The growth of the segment can be attributed to the high effectiveness of vaccines and the increasing inclusion of vaccines in vaccination programs of countries. For instance, countries such as U.K., Australia, Belgium, France, Germany, Iceland, Ireland, the Netherlands, and others have included serogroup C conjugate vaccine in their National Immunization Program.
Based on age group, the infants segment is expected to be the fastest-growing segment over the forecast period owing to the rising prevalence of meningitis. For instance, according to European Centre for Disease Prevention and Control (ECDC), in 2017, IMD incidence was observed to be the highest in infants. In Europe, the prevalence was found to be 8.2 confirmed cases per 100,000 children of age below 1 year. In addition, growing research on available vaccines to determine their impact on preventing the target disease is anticipated to boost the market growth.
The children & adults segment held the largest market share owing to initiatives undertaken by healthcare organizations to vaccinate the adult population and ongoing clinical trials to develop novel vaccines for teenagers. For instance, in February 2020, ACIP released recommended Immunization Schedule for adults, with changes to the administration of the meningococcal B conjugate vaccines.
Based on sales channel, the public sales channel segment held the largest market share and is anticipated to maintain its dominance throughout the forecast period. A large share of the segment can be attributed to the inclusion of major meningococcal vaccine brands, such as Trumenba, Bexsero, Menactra, Nimenrix, Menveo, and others in immunization programs in a major market for vaccination against meningococcal infections. For instance, in July 2020, the government of New South Wales changed the immunization schedule and the government is funding Bexsero for Aboriginal children & some at-risk people and Nimenrix for people at high risk of infection.
The private sales channel is mainly driven by increasing demand for meningococcal vaccines in developing countries. Moreover, increasing disposable income, increasing outbound traveling from work, study, pilgrims for Mecca and Umrah, and increasing awareness is driving the demand for vaccination against meningococcal vaccines through private sales channels.
North America dominated the overall market in terms of revenue in 2021, followed by Europe. Favorable recommendations & support from governments and high R&D investments are some factors driving the North America market. Moreover, a well-developed healthcare structure and an increase in awareness campaigns in the region are anticipated to propel market growth. Market players are also actively involved in an awareness campaign to increase the adoption of the meningococcal vaccine in the region. For instance, in August 2021, GlaxoSmithKline Plc. Launched ASK2BSure campaign for encouraging parents to consult the doctors for meningitis B vaccination of their children.
The Asia Pacific market is expected to grow at a significant rate during the forecast period. The increasing pediatric population and increasing initiatives by the government to combat the rising prevalence of the disease are contributing to the growth of the meningococcal vaccines in this region. Moreover, non-profit organizations present in the region provide information and increase awareness among people and healthcare professionals. Hence, expected to increase the adoption of vaccination against meningococcal infections.
The key players that dominated the global market in 2021 include GlaxoSmithKline plc and Pfizer Inc. The market is expected to experience a shift in the dynamics over the forecast period due to the presence of strong pipeline products. Moreover, companies are involved in developing novel vaccines for meningococcal disease and expanding the application of existing vaccines in terms of age groups. For instance, in June 2020, Pfizer Inc. started Phase III clinical trials of PF-06886992, which is a pentavalent meningococcal vaccine candidate (MenABCWY). Some prominent players in the global meningococcal vaccines market include:
Serum Institute of India Ltd.
Merck & co., Inc.
Walvax Biotechnology Co., Ltd.
Market size value in 2022
USD 3.05 billion
Revenue forecast in 2030
USD 4.92 billion
CAGR of 6.2% from 2021 to 2030
Base year for estimation
2017 - 2020
2022 - 2030
Revenue in USD million and CAGR from 2021 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, brand, serotype, age group, sales channels, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Russia; Belarus; Georgia; Moldova Japan; China; India; Australia; Singapore; South Korea; Thailand; Vietnam; Malaysia; Indonesia; Kazakhstan; Kyrgyzstan; Armenia; Azerbaijan; Tajikistan; Turkmenistan; Uzbekistan; Brazil; Mexico; Argentina; Chile; Cuba; Ecuador; Peru; Colombia; Venezuela; Saudi Arabia; South Africa; UAE; Algeria; Egypt; Tunisia; Iran; Turkey; Iraq; Morocco
Key companies profiled
Pfizer Inc.; Sanofi; Serum Institute of India Ltd.; GlaxoSmithKline plc; Merck & Co., Inc.; Walvax Biotechnology Co., Ltd.
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis on the market trends in each of the sub-markets from 2017 to 2030. For this study, Grand View Research has segmented the meningococcal vaccines market based on type, brand, serotype, age group, sales channel, and region:
Brand Outlook (Revenue, USD Million; 2017 - 2030) (Volume, Number of Doses (in Thousands))
Age Group Outlook (Revenue, USD Million; 2017 - 2030)
Infants (0 to 2 years)
Children And Adults (2 years & above)
Sales Channel Outlook (Revenue, USD Million; 2017 - 2030)
Middle East & Africa
b. The meningococcal vaccine market size was estimated at USD 2.88 billion in 2021 and is expected to reach USD 3.05 billion in 2022.
b. The meningococcal vaccine market is expected to grow at a compound annual growth rate of 6.2% from 2022 to 2030 and is expected to reach USD 4.92 billion by 2030.
b. The quadrivalent vaccine segment is expected to dominate the meningococcal vaccine market with a share of 49.4% in 2021 due to the strong presence of quadrivalent vaccines such as Menactra, Menveo, and Nimenrix.
b. Some key players operating in the meningococcal vaccine market include GlaxoSmithKline plc, Pfizer Inc, Merck & co., Inc., and Serum Institute of India Ltd. among others.
b. Increasing prevalence of meningitis, increasing R&D activities to develop novel vaccines, and increasing government initiatives to reduce disease burden are the major factors driving the meningococcal vaccine market growth over the forecast period.
b. North America held the largest share of 54.4% in 2021 and is expected to register a lucrative growth rate over the forecast period. It is attributable to the favorable recommendations & support from governments and well-established healthcare infrastructure in the region.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for COVID-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for COVID-19 as a key market contributor.